Background: Preliminary studies report no negative and a possible positive impact of Deep Brain Stimulation (DBS) on cognition of patients with Treatment Resistant Depression (TRD). However, these studies neither controlled for practice effects nor compared active with sham stimulation.
Active and sham stimulation did not impact any of the tests differentially.
Conclusions: vALIC DBS neither has a lasting positive nor negative impact on cognition in TRD patients. DBS surgery might have a temporary negative effect on verbal memory.
Introduction
Deep Brain Stimulation (DBS) is a treatment by which specific brain areas are electrically stimulated to modulate activity in surrounding brain tissue.
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In the past 10 years, DBS has been experimentally applied as a treatment for Treatment Resistant Depression (TRD).
186 DBS results in a clinically relevant reduction of symptoms in approximately 40-60% of TRD patients, using the subcallosal cingulate gyrus (SCG), 85, 117, 118, 164, 165 the nucleus accumbens (NAc), 23 the ventral capsule / ventral striatum (VC/VS) 55,124 and the medial forebrain bundle (MFB) 187 as targets for stimulation. Recently, our group has shown DBS of the ventral anterior limb of the internal capsule (vALIC) to reduce depressive symptoms in TRD, which cannot be attributed to placebo effects.
19
Although results on efficacy in TRD are promising, data on the impact of DBS regarding cognitive functioning in TRD patients are scarce. Preliminary studies did not find detrimental effects on cognitive functions in TRD patients following DBS irrespective of target.
17 More specifically, NAc DBS was associated with improvements on tests of verbal and visuospatial memory, attention, and visuospatial functioning in 11 TRD patients. 74 In addition, a combined sample of 10 OCD patients and 11 MDD patients showed improvements on tests of verbal memory and visuospatial organization following VC/VS DBS.
106 Both studies did not find a correlation between symptom decrease and cognitive improvement, suggesting DBS might have a positive impact on cognitive functioning independent of symptomatic improvement. However, no control groups were included in these studies 74, 106 and effects of DBS on cognitive functions have never been directly compared between active and sham stimulation. These limitations hamper interpretation of results since discriminating practice effects from stimulation effects is impossible.
To control for practice effects, we compared cognitive functions of TRD patients treated with vALIC DBS with a matched healthy control (HC) group. In addition, TRD patients were tested in a double blind, randomized active/sham phase to test effects of stimulation directly. With this study we aimed to test the impact of DBS on cognitive functions of TRD patients. In addition, we investigated the relation between symptom improvement and cognitive change.
74

Methods
Participants
We included 25 TRD patients, who were recruited from referrals to the outpatient clinics of the Academic Medical Center (Amsterdam) and the St Elisabeth Hospital (Tilburg), the Netherlands, between March 2010 and May 2014. In addition, we included 21 healthy controls (HC) matched on age, gender and educational level. HC were recruited with advertisements in the Academic Medical Center and got a financial compensation for participation (A C25 per test session). The Medical Ethical Board of the Academic Medical Center approved the study and all participants gave their written informed consent. This study was an addition to a clinical trial registered in the Dutch Trial Register. a Inclusion criteria for TRD patients were: (1) aged between 18 and 65; (2) a primary diagnosis of MDD which was treatment resistant. Treatment resistance was defined as a failure of at least the following antidepressant therapies in adequate dosage and duration: two distinctly different classes of second generation antidepressants (e.g. Selective Serotonin Reuptake Inhibitor, Selective Norepinephrine Reuptake Inhibitor) and one trial of a tricylic antidepressant (TCA) and one trial of TCA with lithium addition and one trial of a Monoamine Oxidase Inhibitor and ≥ 6 sessions of bilateral ECT. Patients who fulfilled the above criteria and were kept stable with maintenance ECT, but relapsed after discontinuation of maintenance ECT were also eligible; (3) a Hamilton Depression Rating Scale -17 items (HAM-D-17) score of at least 18; (4) a Global Assessment of Function (GAF) score of a maximum of 45, which was persistent for at least 2 years.
Exclusion criteria for TRD patients were: (1) the presence of a bipolar disorder or a (history of) psychosis; (2) substance abuse in the past 6 months; (3) comorbid neurologic disorders; (4) an unstable physical condition; and (5) pregnancy or general contra-indications for DBS surgery. HC were matched with DBS patients on gender, age and level of education. Healthy controls were excluded if they or their first-degree relatives had a history of a psychiatric disorder.
DBS surgery and optimization
DBS surgery and optimization were described in detail earlier.
19 In summary, a neurosurgeon implanted bilateral four-contact electrodes (model 3389, Medtronic) following a trajectory through the anterior limb of the internal capa http://www.trialregister.nl/, nr. 2118 75 sule with the deepest contact point in the nucleus accumbens and the three upper contact points in the ventral part of the capsule. The electrodes were connected to an Activa PC (Medtronic) stimulator. Following a three-week recovery period after surgery, a standardized, open-label DBS parameter optimization period of maximally 52 weeks started. A psychologist or psychiatrist tested combinations of active contacts, voltage, pulse width and frequency for optimal efficacy. We strived to keep medication stable during the open label phase, but psychiatrists were allowed to change medication on clinical indication (see Table 6 .4 in the supplementary information for medication use of patients at different sessions).
After the open phase, patients entered the randomized, double blind crossover phase consisting of two blocks of six weeks during which the DBS stimulator was on (active stimulation) or off (sham stimulation). The phases were terminated if the treating psychiatrist or research team deemed it clinically indicated and the HAM-D-17 ≥ 15, or if the patient requested discontinuation. In these cases, patients crossed over to the next phase while blinding was maintained. Medication and DBS settings (except for stimulation 'on' or 'off') were kept stable during the crossover phase.
Study design
Trained psychologists assessed symptom severity and cognitive functions of patients and controls at 5 time points (see Figure 1 ): three weeks before DBS surgery (Baseline), three weeks after surgery with stimulation still inactive (T1), after the optimization of DBS settings (T2), and after the first (T3) and second crossover block (T4). Patients and raters were blinded for the stimulation setting at T3 and T4. HC were assessed at inclusion (Baseline), 6 weeks after Baseline (T1), and 16-20 weeks after Baseline (T2).
Outcome measures
Symptom severity was assessed with the investigator rated Hamilton Depression Rating Scale -17 items (HAM-D-17, range 0-52).
79 Response was defined as ≥ 50% reduction of HAM-D-17 at T2 compared to baseline. In case of drop-out before T2 the last HAM-D-17 score in the optimization phase was used to define response. Reaction Time (RTI): RTI measures psychomotor speed and has two subtests: Simple (RTI-Sim) and 5 Choices (RTI-5C). Participants have to release a button and touch either the center (RTI-Sim) or one of five spots on the screen (RTI-5C) as quickly as possible when a yellow dot flashes on the screen. For each subtest the time to release the button in milliseconds (ms) is analyzed.
Verbal Recognition Memory -delayed (VRMd):
VRMd measures delayed verbal memory. This is a repetition of the VRMi after a delay of approximately 30 minutes and also consists of a free recall (VRMd-FR, 0-18 correct) and recognition (VRMd-Rec, range 0-36 correct) outcome measure.
Stockings of Cambridge (SOC):
SOC measures planning ability and is a computerized version of the Tower of London. Subjects have to reproduce a specific configuration of 3 colored balls by moving the 3 balls in as few moves as possible. Outcome measure is number of moves exceeding the minimum needed to solve the exercises, range 0-68). (GEE) were used for the count data (VRMi-FR, VRMi-Rec, IED, VRMd-FR, VRMdRec, SOC, PAL, GNT), and 3 linear mixed models (LMM) for the continuous data (RVP, RTI-Sim, RTI-5c). GEE and LMM models contained the different outcome measures as dependent variable and Condition (TRD, HC), Session (Baseline, T1, T2) and the interaction Condition X Session as independent variables. To test differences between TRD patients and HC at Baseline, we inspected estimates at Baseline from these models. To test for changes from Baseline to T2, we inspected the Session and Session X Condition interaction of the models. Post-hoc, we explored differences between Responders and Non-responders from Baseline to T2 by repeating the same models with Responder Status (Responder, Non-Responder), Session and Responder Status X Session interaction as predictors. In case of significant interactions, we corrected for benzodiazepine use by including equivalent benzodiazepine dosage as a covariate (using The Ashton Manual).
Paired Associates Learning (PAL)
:
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To test possible differences between active and sham stimulation, we executed 8 GEE for the count data and 3 LMM. Cognitive outcome measures were included as dependent variables. Period (T3, T4) and Stimulation Setting (Active, Sham) were included as independent variables and the Period X Stimulation Setting interaction was included to test for carry-over effects. Score at the start of the crossover phase of the relevant dependent variable (i.e. score at T2) was included as covariate. Post-hoc, we explored differences between Responders and Non-responders during active compared to sham stimulation, in which Responder Status, Stimulation Setting and Responder Status X Stimulation Setting interaction were included as predictors.
For the primary analyses, we considered P ≤ 0.01 significant to account for multiple testing. P-values between 0.01 and 0.05 are reported as trends. For the post-hoc analyses we considered P ≤ 0.05 significant and 0.05 < P < 0.1 78 as trends, given the smaller sample size and the exploratory nature of these analyses. Figure 1 depicts the drop-outs during the study: of the 25 TRD patients who started the study, we tested 20 at T2, and 16 at T3 and T4. We tested all 21 HC at T1 and T2. Due to hardware failures, some of the data was lost (see Table 6 .2 and 6.3 for actual number of participants with available data). The average follow-up duration between Baseline and T1 was shorter in TRD patients (36.1 days, SD: 13.4) compared to HC (46.7 days, SD: 11.1). However, the follow-up duration between Baseline and T2 was considerably longer in TRD patients (Mean: 457.9 days, SD: 209.3) than HC (155.0 days, SD: 20.0). The average durations of the first (21.13 days, SD: 11.14) and second crossover phase (18.56 days, SD: 13.14) were similar. However, patients remained longer in the active (25.3 days, SD: 11.3) than in the sham phase (14.4 days, SD: 10.5), irrespective of whether the active phase came first or second. DBS optimization resulted in a significant decrease of HAM-D score in an Intent-to-Treat analysis (F(1,640)=10.3, P=0.001). Following DBS treatment 10 TRD patients (40%) were classified as Responders and 15 patients (60%) as Non-responders. Of the 20 patients tested at T2, 9 were responders (45%) and 11 were non-responders (55%). Of the 16 patients tested in the crossover phase (T3 and T4), 9 were responders (56%) and 7 were non-responders (44%). No differences on any descriptive variables were found between patients who dropped out before and those who partici-79 pated in the crossover phase , except for the ratio non-responders/responders (Fisher's P=0.04). In the double blind crossover phase, patients had an average HAM-D score of 13.6 (SD: 7.8) following the active and 23.1 (SD: 5.1) following the sham phase. After correction for carryover effects, Period, and Depression score at T2 the mixed models showed a significant lower HAM-D-17 score in the active stimulation phase compared to the sham stimulation phase (F(1,13)=23.5, P<0.001). 
Results
Baseline
Effects of DBS treatment
A significant interaction effect of Session by Condition was found on immediate verbal recognition (VRMi-Rec, Session X Condition: Wald χ 2 (2)=14.7, P=0.001). Post-hoc inspection of the data revealed the average performance of TRD patients did not change between Baseline and T1 (after surgery with stimulation off), whereas HC improved from Baseline to T1. No significant interaction effects were found on any of the other tests (all P>0.05). 
A significant improvement over sessions irrespective of Condition was found on tests measuring delayed verbal recall (Wald
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phase on both tests. To correct for changes in benzodiazepine use over time, we added this as a covariate in the analyses of these two outcome measures. The interaction effect Responder Status X Session remained significant for VRMi-FR (Wald χ 2 (2)=14.3, P=0.001), but not for delayed verbal recall (VRMd-FR: Wald χ 2 (2)=4.5, P=0.103), although benzodiazepine use was not a significant predictor in both analyses (VRMi-FR: Wald χ 2 (1)=1.4, P=0.243, VRMd-FR: Wald χ 2 (1)=1.7, P=0.188). Although Responders improved more than NonResponders on these tests, their performance was still worse than HC at T2 on immediate recall (Responders: Mean: 6.5 words, SD: 1.7; Non-responders: 5.5 words, SD: 1.8; HC: Mean: 8.7 words, SD: 2.5), as well as delayed recall (Responders: Mean: 5.3 words, SD: 2.5; Non-responders: 4.2 words, SD: 2.9; HC: Mean: 7.6 words, SD: 4.1).
Active / Sham phase
Nine patients were randomized to 'Active-Sham', 7 patients to 'Sham-Active'. Table 6 .3 lists the test-scores during the crossover phases of TRD patients. We found no carry-over effects on any of the tests, so these interaction terms were removed from all models. No significant differences between Active and Sham stimulation were found on any of the tests. However, we did find trends towards better functioning on tests of object naming (GNT: Wald χ 2 (1)=4.3, P=0.038) and choice reaction time (RTI-5C: F(1,14.0)=4.6, P=0.050) in active compared to sham stimulation. Performance on Verbal Recognition Memory (VRM) on Baseline, T1 (after surgery with DBS off in patients, after 6 weeks in healthy controls) and T2 (after optimization of DBS settings in patients, after 18 weeks in healthy controls). Abbreviation: HC=Healthy Controls. Error bars represent 95% confidence intervals.
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Discussion
The aims of this study were to assess whether cognitive functions of TRD patients change following DBS and whether these changes are related to treatment response. TRD patients show impaired verbal and visuospatial memory, attention, and object naming compared with HC. DBS surgery may have a (temporary) adverse effect on immediate verbal memory. DBS did not affect cognitive functioning in TRD patients, neither during optimization of DBS parameters, nor active nor sham stimulation. Verbal memory of responders did, however, improve compared with non-responders.
Most findings are in line with the literature. Impairment of TRD patients compared to HC in a wide range of cognitive domains is in line with meta-analyses of cognitive functioning of depressed patients. 173,215 Furthermore, vALIC DBS does not result in cognitive decline in TRD patients as seen in previous DBS studies targeted at the striatum, 74 internal capsule 106 or SCG. 24, 136, 140, 195 Some authors have suggested a cognitive enhancing effect of DBS, 74,106 mainly because the cognitive improvement was uncorrelated with symptom improvement. However, practice effects could not be discriminated from stimulation effects in these studies, since they did not follow HC groups longitudinally.
74,106
In our study, cognitive functioning of TRD patients improved in the same rate as HC, suggesting this reflects practice rather than cognitive enhancement. Furthermore, cognitive performance did not change during sham stimulation despite a rapid reinstatement of symptoms, indicating DBS does not directly affect cognitive functioning. Possibly, a lack of power prevented detecting cognitive enhancement. However, the sample of 25 patients followed here is larger than previously studied samples and we also did not find any trends in the data to suggest we would have established cognitive improvements beyond practice effects with a larger sample.
Our exploratory analysis showed verbal memory functions of responders improved more than non-responders, which is in contrast with aforementioned studies. 74, 106 In further support of the relationship between response and memory improvement, responders performed better on verbal memory tasks during active than sham DBS, whereas non-responders performed equally during active and sham stimulation. Improvement of verbal memory functions appears to depend on treatment response and might reflect a 'state' deficit. This is consistent with literature on verbal memory improvement alongside response to other antidepressant treatment modalities.
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Unexpectedly, we found a decline on tests of verbal and visuospatial memory, and cognitive flexibility from the first to second crossover phase in patients. Speculatively, this could be due to reduced motivation after performing the 86 cognitive battery 3 times in an 8-week period, or the parallel tests were coincidentally more difficult at T4 than at T3.
It is somewhat surprising DBS does not affect cognitive functions, considering vALIC DBS likely modulates frontostriatal pathways.
66,112 Depressed patients show abnormal neural functioning in these pathways, which also have been implicated in reward and affective processing.
61,181 However, affective and reward processing are not explicit components of the neuropsychological tests used in this study. In future studies it would be interesting to include tasks which do take this into account, such as affective go/no-go, reward processing or gambling tasks.
A limitation of this study is the shorter follow-up duration from BL to T2 in HC compared to patients. This might have resulted in smaller practice effects in patients than controls and consequently, an underestimation of the cognitive improvement. However, based on a meta-analysis of factors contributing to practice effects, we estimate these to be small at T2 given the use of parallel tests and the follow-up time of at least several months in a participant group of this age.
32 In addition, the lack of differences in the crossover phase does not point towards a direct effect of DBS on cognition. A second limitation is the tapering off of antidepressants and benzodiazepines in some responders during the study, which could partly explain the memory improvement. However, antidepressants most likely do not impact or only have a small positive effect on cognitive functioning.
14,175 The literature shows that benzodiazepines do have a clear negative impact on memory and attention, 205 but explained only a small amount of memory performance in this study. Thirdly, only 16 of the 25 patients participated in the cross-over phase. The group of participating patients consisted of relatively more responders than those who dropped out, which could have biased the results towards better performance in the active compared to the sham phase. Despite this possible bias, we did not find any differences between active and sham stimulation with essentially equal scores in both phases. Therefore, this possible bias most likely did not majorly impact the results.
To conclude, vALIC DBS does not result in cognitive decline in TRD patients lending further support for DBS as a safe treatment regarding cognitive functioning. In addition, we do not find support for a possible cognitive enhancing effect of vALIC DBS.
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